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Response to 250 and 1 g ACTH Stimulation in Patients
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Context: Although the production and metabolic clearance rate of
cortisol is increased during thyrotoxic state, the net effect on adre-
nocortical reserves is not clear.
Objective: We assessed circulating ACTH levels, cortisol binding
globulin (CBG), and adrenocortical reserves in hyperthyroid patients
(before and after carbimazole therapy) and healthy controls.
Design and Setting: This was a case-control investigative study in
a tertiary care setting.
Patients and Methods: Plasma ACTH and free cortisol index (FCI;
serum cortisol/CBG) were measured in 49 consecutive patients with
hyperthyroidism and 50 controls. ACTH1–24 stimulation tests (250
and 1 g) were carried out in the first 29 patients and 15 controls.
Peak FCI less than themean3 SD of healthy controls was considered
subnormal. ACTH1–24 stimulation tests were repeated in 24 patients
in the euthyroid state.
Results: The mean basal plasma ACTH and FCI were higher and
CBG was lower in thyrotoxic patients in comparison with controls.
The peak cortisol was less than 18 g/dl in 10 of 29 and 14 of 29 on
250 and 1 g ACTH1–24 stimulation. Peak FCI was subnormal only
in three of 27 (11.1%) and two of 21 (7.4%) on 250 and 1 g ACTH1–24
stimulation, respectively. The mean plasma ACTH, basal FCI, and
subnormal peakFCI (two of the three) normalized after euthyroidism.
Plasma ACTH and FCI did not correlate with severity of
thyrotoxicosis.
Conclusions:Up to 11% of thyrotoxics have subnormal peak FCI on
ACTH1–24 stimulation. Such changes occur despite high basal plasma
ACTH and FCI. Use of FCI, rather than total cortisol, is required for
the interpretation of cortisol values in thyrotoxicosis due to the vari-
ation in CBG. (J Clin Endocrinol Metab 92: 1693–1696, 2007)
DIARRHEA AND WEIGHT loss are prominent clinicalfeatures of thyrotoxicosis (1, 2). Similar symptoms are
observed in patients with adrenocortical insufficiency (3).
Although the metabolic clearance and production rate of the
cortisol is enhanced during thyrotoxicosis (4), its net effect on
adrenocortical reserves is under investigation (5–8). Cur-
rently 250 or 1 g synthetic ACTH1–24 tests are used to assess
adrenocortical reserves. There have been three studies in
which subnormal adrenal reserves have been reported in
20–30% of thyrotoxic patients after iv ACTH1–24 stimulation
(5–8).
In thyrotoxicosis, serum cortisol binding globulin (CBG)
levels are reduced and return to normal after induction of the
euthyroid state (9, 10). Reduction in cortisol reserves in thy-
rotoxic patients and its normalization after euthyroidism
(5–8) could be due to variation related to CBG. In stress, like
thyrotoxicosis, circulating ACTH values are expected to in-
crease and more so in presence of adrenal insufficiency. We
assessed plasma ACTH and adrenocortical response to 250
and 1 g of ACTH1–24 stimulation in patients with thyro-
toxicosis before and after attainment of euthyroidism, taking
into consideration changes in CBG levels, in the interpreta-
tion of cortisol response.
Subjects and Methods
Subjects
Study included 49 consecutive patients with hyperthyroidism [39
females; mean  sd age, 38.0  12.3 yr; body mass index (BMI), 20.1 
4.0 kg/m2; median duration of symptoms, 12 months] attending endo-
crine clinic of the All India Institute of Medical Sciences and 50 healthy
controls. Patients with thyrotoxic crisis and history of recent glucocor-
ticoid intake were excluded. Hyperthyroidism was diagnosed based on
the Volpe’s criteria with Wayne’s score greater than 19, serum total T4
and TSH in the hyperthyroid range, and high 131I uptake (11). Forty-two
patients had diffuse thyromegaly, five hadmultinodular goiter, and two
had solitary toxic nodule on 99mTc pertechnetate thyroid scan. The
healthy controls were volunteers (mean age, 35.4  7.6 yr; BMI, 22.8 
3.2 kg/m2) who had normal serum total T4 and TSH. Ten milliliters of
venous blood were drawn from all study subjects at 0800 h for mea-
surement of baseline plasma ACTH, serum total cortisol, T4, TSH, thy-
roid peroxidase antibodies (TPOAb), and CBG. Intravenous ACTH1–24
(250 and 1 g; Ciba-Geigy, Basel, Switzerland) stimulation tests were
performed in the initial 29 consecutive patients and 15 healthy controls.
One microgram ACTH1–24 per milliliter saline was prepared afresh
before each test by mixing 250 g ACTH1–24 in 250 ml of 0.9% saline in
a plastic container (12). One and 250gACTH1–24 stimulation tests were
performed between 0800 and 0900 h on d 1 and 2, respectively. Blood
was drawn for cortisol estimation at15, 0,30,60, and90min after
ACTH bolus. The free cortisol index (FCI) was calculated by serum
cortisol/CBG (nanomoles per milligram).
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Definitions of subnormal cortisol response
The mean peak FCI during 250 and 1 g ACTH1–24 stimulation tests
in healthy controls was 12.4 1.4 and 9.9 1.04 nmol/mg, respectively.
Peak FCI in 250 and 1 g ACTH1–24 stimulation tests were considered
subnormal in thyrotoxicosis if the value was less than the mean 3 sd
of healthy controls (8.2 and 6.8 nmol/mg, respectively).
Treatment
Patients were treatedwith carbimazole (10–15mg, three times a day).
Serum total T4 wasmeasured at an interval of every 2months. Themean
duration to achieve euthyroidism was 4  1 months. Twenty-four pa-
tients were reassessed after clinical (BMI, 22.5  3.8 kg/m2) and bio-
chemical euthyroidism (mean interval 7  1 months), and repeat tests
were performed including fasting serum CBG, plasma ACTH, and
ACTH1–24 stimulation. The Institutional Ethics Committee of All India
Institute of Medical Sciences approved the study protocol, and written
informed consent was obtained from all subjects.
Hormone assays
Serum and plasma samples were stored at 20 C and assays were
performed together in multiple batches by electrochemiluminescence
(Elecsys 2010; Roche, Mannheim, Germany). CBG and plasma ACTH
weremeasured by RIA (Biosource Technologies, Inc., Nivelles, Belgium)
and immunoradiometric kit (DiaSorin, Stillwater, MN). The normal
range for plasma ACTH, 0800 h serum cortisol, total T4, TSH, TPOAb,
and CBG were 6.0–56.7 pg/ml, 6.2–19.4 g/dl, 5.1–14.1 g/dl, 0.3–4.2
IU/ml, less than 34.0 IU/ml, and 22–154 mg/liter, respectively. The
intra- and interassay coefficients of variation for serum cortisol was
1.3–1.6%; CBG, 3.9–5.5%; and 4.7–8.7% for TPOAb and other hormones.
Statistical analysis
SPSS software (version 11.5; SPSS, Inc., Chicago, IL) was used for
statistical analyses. The data are given as mean sd. ANOVA followed
by Bonferroni post hoc test was used to compare mean of various vari-
ables in different groups. Paired t test was used to compare differences
in the mean of variables before and after carbimazole therapy. Fisher’s
exact or 2 testswith Yates’ correctionwere used to assess the differences
in the frequency of nonparametric variables. Pearson’s correlation co-
efficientswere used for correlation analysis. The area under curve (AUC)
for FCI was calculated by the trapezoidal rule. P  0.05 was considered
significant.
Results
Table 1 shows the clinical characteristics, mean plasma
ACTH, serum CBG, total cortisol, and FCI at baseline and
after ACTH stimulation in thyrotoxic (before and after treat-
ment) and the control groups.
Serum CBG, plasma ACTH, and FCI in thyrotoxic state
Themean serumCBG, basal plasmaACTHvalue (median,
32.0 pg/ml; range 11.0–400.0 pg/ml), and frequency of su-
pranormal plasma ACTH values were higher in thyrotoxic
patients than healthy controls (Table 1). Although the mean
basal cortisol was comparable between thyrotoxic patients
and the controls, the mean basal FCI was significantly higher
in thyrotoxic patients. All nine thyrotoxic patients and two
healthy controls with supranormal plasma ACTH had nor-
TABLE 1. Comparison of baseline characteristics, CBG, and FCI in patients with thyrotoxicosis before and after carbimazole therapy and
healthy controls (ANOVA)
Parameters Thyrotoxicosis beforetreatment Thyrotoxicosis after treatment Controls
n (males:females) 49 (10:39) 24 (5:19) 50 (26:24)
Mean age (yr) 38.0  12.3 NA 35.4  7.6
Mean total T4 (g/dl) 20.2  7.0
a 10.2  3.7b 8.1  1.8b
Mean TSH (IU/ml)† 0.03  0.03a 1.51  2.47b 2.53  1.65c
Mean serum CBG (mg/liter)* 42.0  14.3 (n  40)a 60.1  11.6b 54.2  7.3b
Mean basal cortisol (g/dl) 11.5  5.0 12.8  5.6 11.1  4.0
Mean basal FCI (nmol/mg) 7.9  3.3a 6.0  2.7b 5.9  2.1b
Mean basal ACTH (pg/ml)† 48.8  58.5a 31.8  20.0a,b 28.7  12.0b
Supranormal ACTH (%) 9/49 (18.4%)a 1/24 (4.2%)a,b 2/50 (4.0%)b
250 g ACTH stimulation test n  27 n  21 n  12
Mean peak FCI (nmol/mg) 13.6  4.1 13.1  2.6 12.4  1.4
Mean timing of peak FCI (min) 78.6  21.8 82.5  16.0 87.5  8.7
Mean FCI 30 min (nmol/mg) 11.3  3.6 11.1  2.1 10.2  1.3
Mean FCI 60 min (nmol/mg) 12.5  4.0 12.3  2.5 11.7  1.5
Mean FCI 90 min (nmol/mg) 13.3  4.3 13.0  2.8 12.4  1.4
Mean AUC for FCI (nmolmin/mg) 1024  321 990  189 917  199
Peak FCI  3 SDS 3/27 (11.1%) 1/21 (4.8%) 0/12 (0.0%)
Peak cortisol  18.0 g/dl (%)** 10/29 (34.5%)a 1/24 (4.2%)b 0/12 (0.0%)b
1 g ACTH stimulation test n  27 n  21 n  15
Mean peak FCI (nmol/mg) 11.5  4.3 10.5  2.0 9.9  1.0
Mean timing of peak FCI (min) 40.3  18.4 30.0  0.0 36.0  12.4
Mean FCI 30 min (nmol/mg) 11.1  3.9 10.5  2.0 9.8  1.1
Mean FCI 60 min (nmol/mg) 8.8  3.8 8.6  1.9 8.3  1.3
Mean FCI 90 min (nmol/mg) 6.8  4.5 7.1  1.6 6.6  1.5
Mean AUC for FCI (nmolmin/mg) 817  301 766  152 724  93
Peak FCI  3 SDS 2/27 (7.4%) 1/21 (4.8%) 0/12 (0.0%)
Peak cortisol  18.0 g/dl (%)** 14/29 (48.3%) 5/24 (20.8%) 3/15 (20.0%)
Data in the same row with different superscript letters are significantly different from each other. Basal cortisol and basal FCI are the mean
of 0800 h serum cortisol values on the days of 1 and 250 g ACTH stimulation. SDS, SD score. FCI  cortisol/CBG. SI unit conversion factors:
cortisol, 1 g/dl  27.59 nmol/liter; ACTH, 1 pg/ml  0.2202 pmol/liter.
† P values were calculated after log transformation.
* and **, n is different from the whole group.
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mal basal serum cortisol. Eight of nine patients with su-
pranormal plasma ACTH had Graves’ disease with TPOAb
titers greater than 100 IU/ml. The mean basal FCI was com-
parable in thyrotoxic patients with andwithout supranormal
plasma ACTH.
ACTH1–24 stimulation test in patients with thyrotoxicosis
and controls
ACTH1–24 stimulation test (250g). Themean FCI at30,60,
and 90 min, peak response, and AUC for FCI was com-
parable in patients with thyrotoxicosis and healthy controls
(Fig. 1). Although peak cortisol response was less than 18.0
g/dl in 10 of 29 thyrotoxics, only three had subnormal peak
FCI. All three subjects with subnormal peak FCI had peak
cortisol values less than 18.0 g/dl. Two of these three also
had supranormal ACTH.
ACTH1–24 stimulation test (1g). The pattern of adrenocortical
response was similar to that observed with 250 g ACTH1–24
stimulation. However, the mean FCI response including its
peak and AUC were higher after 250 g ACTH1–24 in com-
parison with 1 g ACTH1–24 stimulation in patient and the
control groups (Table 1 and Fig. 1). Although 14 of 29 of
thyrotoxics and three of 15 healthy controls had peak cortisol
less than 18.0 g/dl, subnormal peak FCI was observed in
only two thyrotoxic patients. Both these patients also had
subnormal peak FCI on 250 g ACTH1–24 stimulation.
Changes in serum CBG, plasma ACTH, and FCI after
carbimazole therapy
The mean plasma ACTH and basal FCI decreased and
mean serum CBG significantly increased after attainment of
euthyroidism. The mean CBG, plasma ACTH, and basal FCI
in thyrotoxic patients after euthyroidism were not signifi-
cantly different from that in healthy controls (Table 1). The
mean FCI response including its peak andAUC after 250 and
1gACTH1–24 stimulationwere comparable before and after
treatment. Two of the three thyrotoxics with subnormal peak
FCI on 250 g ACTH1–24 test showed normal plasma ACTH
and peak FCI response after euthyroidism. The third patient
with subnormal peak FCI and elevated plasmaACTHduring
the euthyroid state at 6 months showed normal plasma
ACTH at 10 months of follow-up.
Severity of hyperthyroidism and adrenocortical reserves
All 49 patients were stratified in two groups at a median
serum total T4 level of 22.2g/dl. Themedian plasmaACTH
[28.0 pg/ml, range (11–110 pg/ml) vs. 34.0 pg/ml (range
11–400 pg/ml), P 0.18], serum CBG (47.3 17.1 vs. 44.1
12.7 mg/liter, P 0.59), and basal FCI (7.4 3.3 vs. 8.7 4.0
nmol/mg, P  0.35) were comparable in the two groups.
Similarly mean FCI at 30, 60, and 90 min, peak and
AUC, and the frequency of subnormal peak FCI after 250 and
1 g ACTH1–24 stimulation were comparable in the two
groups. Pearson’s test showed no relationship among total
T4, plasma ACTH, and basal and peak FCI in the thyrotoxic
state.
Discussion
Holst in 1935 first reported increase in the adrenal size on
autopsies of thyrotoxic patients (13). Adrenal glands were
moderately enlarged on computerized tomography in
Graves’ disease (7). Although increased circulating ACTH in
thyrotoxicosis is linked to skin hyperpigmentation, there are
limited data on plasmaACTH levels in them.Hilton et al. (14)
reported increased ACTH-like activity in thyrotoxicosis.
Subsequently Yamakita et al. (8) and Gao et al. (15) reported
mild elevation of plasma ACTH in Graves’ disease that nor-
malized after antithyroid drugs. In the current study, the
mean plasma ACTH and FCI values were higher in patients
with thyrotoxicosis than that in healthy controls and nor-
malized after attainment of euthyroidism. Presence of adre-
nal enlargement and supranormal plasma ACTH coupled
with significantly higher basal FCI suggest that pituitary-
adrenal axis is stimulated in thyrotoxic state.
On the other hand, there are reports of subnormal peak
cortisol on ACTH1–24 stimulation tests in thyrotoxic subjects
(5–8). Peak cortisol less than 18 g/dl during ACTH1–24
stimulation is considered subnormal (16). In the current
study, the peak cortisol was also less than 18.0 g/dl in 34.5
and 48.3% of thyrotoxic patients during 250 and 1 g
ACTH1–24 stimulation tests, respectively.
Several investigators suggested adjustment for variation
in serum CBG in interpretation of cortisol values (17–19).
Measurement of free cortisol would exclude effects related to
alteration in serum CBG. Ratio of total serum cortisol and
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FIG. 1. Mean FCI at baseline (0 min) and at30,60, and90 min.
ACTH1–24 stimulation tests during 250 g (A) and 1 g (B) in thy-
rotoxic subjects (), euthyroid state (f), and healthy controls (Œ). *
and †, Significant difference (P  0.05) in baseline serum FCI in
thyrotoxic vs. euthyroid state and healthy controls.
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CBG, i.e. FCI, has also been shown to correlate with free
cortisol levels (18). Recently le Roux et al. (19) compared peak
FCI and peak total cortisol values in 31 subjects during the
perioperative period of major surgeries. Peak FCI was nor-
mal in all seven subjects in whom peak cortisol was less than
18.0 g/dl (19). There is no study in which adrenocortical
reserves have been assessed using FCI in ACTH1–24 stimu-
lation tests in thyrotoxic patients. The observation of the
current study showing significant reduction in CBG in thy-
rotoxic patients and its normalization after euthyroidism is
in accordance with the previous studies (9, 10). Interestingly,
majority of the patients who had peak cortisol values less
than 18g/dl on 250 and 1gACTH1–24 stimulation showed
normal peak FCI response. Using peak FCI less than 3 sd
score of the healthy controls as the definition of subnormal
peak FCI during ACTH1–24 stimulation test, only three of 27
thyrotoxic patients (11%) had subnormal response on 250 g
ACTH1–24 stimulation.
Overall, the observations of high circulating ACTH and
basal FCI in thyrotoxicosis but impaired peak FCI response
in 11% support adrenal hyperactivity with the possibility of
adrenal exhaustion in a subset of them. Abnormalities ob-
served in the pituitary-adrenal axis were reversible after
attainment of euthyroidism. Coexistent autoimmune adre-
nalitis is reported in up to 5%of patientswithGraves’ disease
(20). Reversible nature of abnormalities in peak FCI suggests
autoimmune adrenalitis as the unlikely cause of subnormal
reserves.
Thus, up to 11% of thyrotoxics have subnormal peak FCI
on ACTH1–24 stimulation. Such changes occur despite high
basal plasma ACTH and FCI. Use of FCI, rather than total
cortisol, is required for the interpretation of cortisol values in
thyrotoxicosis due to the variation in CBG. Further studies
involving direct measurement of free cortisol would be help-
ful in assessing adrenocortical reserves in patients with
thyrotoxicosis.
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